NCT00616317

Brief Summary

The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
166mo left

Started Sep 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress59%
Sep 2006Jan 2040

Study Start

First participant enrolled

September 1, 2006

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

February 4, 2008

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 15, 2008

Completed
31.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2040

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2040

Last Updated

December 5, 2025

Status Verified

December 1, 2025

Enrollment Period

33.4 years

First QC Date

February 4, 2008

Last Update Submit

December 3, 2025

Conditions

Antiphospholipid Syndrome

Keywords

Antiphospholipid Syndrome

Outcome Measures

Primary Outcomes (1)

  • Long term survival

    10 year

Eligibility Criteria

Age1 Minute - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pediatric Nephrology Clinic at University of California, Davis

You may qualify if:

  • years of age or younger at the onset of disease
  • Presence of Vascular Thrombosis
  • UC Davis patient
  • Presence of at least one Laboratory criteria including: Anticardiolipin antibody, Anti-B glycoprotein-I antibody or Lupus anticoagulant in plasma

You may not qualify if:

  • Infants born to mothers with APS
  • Infants with congenital thrombophilia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Davis Medical Center

Sacramento, California, 95817, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Antiphospholipid Syndrome

Condition Hierarchy (Ancestors)

Autoimmune DiseasesImmune System Diseases

Study Officials

  • Lavjay Butani, M.D.

    University of California, Davis

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lavjay Butani

CONTACT

(916) 734-8118

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2008

First Posted

February 15, 2008

Study Start

September 1, 2006

Primary Completion (Estimated)

January 1, 2040

Study Completion (Estimated)

January 1, 2040

Last Updated

December 5, 2025

Record last verified: 2025-12

Locations

US(1)